Online inquiry

IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10038MR)

This product GTTS-WQ10038MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10038MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12516MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ15268MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ773MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ13965MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ14900MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ7867MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ4430MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ6581MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DC-1630423
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW